Acasti Pharma Inc Class A ACST
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACST is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $3.19
- Day Range
- $3.06–3.17
- 52-Week Range
- $1.72–3.84
- Bid/Ask
- $2.50 / $3.10
- Market Cap
- $28.86 Mil
- Volume/Avg
- 9,713 / 29,153
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 32
- Website
- https://www.acastipharma.com
Valuation
|
Metric
|
ACST
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.45 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ACST
Financial Strength
|
Metric
|
ACST
|
|---|---|
Quick Ratio | 14.73 |
Current Ratio | 15.19 |
Interest Coverage | — |
Quick Ratio
ACST
Profitability
|
Metric
|
ACST
|
|---|---|
Return on Assets (Normalized) | −8.66% |
Return on Equity (Normalized) | −10.19% |
Return on Invested Capital (Normalized) | −11.01% |
Return on Assets
ACST
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cxcjxsjt | Knnng | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rdfsxxdgv | Lskwfkh | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bbskghcq | Mzldlvg | $98.1 Bil | |
MRNA
| Moderna Inc | Mmsrvvm | Fnyz | $39.1 Bil | |
ARGX
| argenx SE ADR | Ctcfxtz | Lvl | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Xwfgxdyg | Yslzz | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ljlpgnwn | Bwqtj | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kyczysj | Vsfmk | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dxhrbgsdwj | Jxxzjr | $12.5 Bil | |
INCY
| Incyte Corp | Pgpdgzgwp | Dfdqf | $11.9 Bil |